PBLSParabilis Medicines, Inc.vs its industry peers
A metric-by-metric comparison of Parabilis Medicines, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PBLSEsta | $4.9B#8 | — | 4.7x#8 | — | — | — | — | 0.0%#4 | — | — | — | — |
| COGT | $5.7B#1 | — | 10.7x#12 | 726.6x#8 | -65.0%#8 | -28.6%#11 | -4235.3%#8 | -61.8%#15 | -84.3%#7 | — | 166.8%#5 | — |
| DNTH | $5.6B#2 | — | 4.8x#9 | 2767.2x#10 | -67.3%#9 | -91.1%#14 | -8739.3%#10 | -13.9%#10 | — | — | 159.0%#8 | — |
| PTCT | $5.6B#3 | — | — | 3.3x#2 | 114.5%#3 | 288.0%#2 | 50.1%#1 | — | — | — | 11.3%#14 | — |
| LGND | $5.6B#4 | 29.1x#3 | 5.8x#11 | 21.0x#5 | 60.4%#4 | 3186.6%#1 | 15.3%#2 | 12.9%#3 | 3.0%#3 | — | 70.7%#9 | — |
| XENE | $5.5B#5 | — | 4.4x#7 | 736.4x#9 | — | -47.6%#12 | -4974.3%#9 | -27.8%#12 | -32.5%#5 | — | 55.5%#11 | — |
| ERAS | $5.3B#6 | — | 14.7x#14 | — | — | 23.0%#6 | — | -34.4%#13 | — | — | 815.6%#1 | — |
| EWTX | $5.0B#7 | — | 11.1x#13 | — | — | -25.4%#10 | — | -0.0%#5 | -50.9%#6 | — | 228.7%#2 | — |
| ACAD | $4.7B#9 | 12.3x#1 | 3.6x#3 | 4.4x#3 | 11.9%#6 | 73.0%#3 | 9.8%#4 | 29.9%#1 | 11.4%#1 | — | 13.1%#13 | — |
| MANE | $4.5B#10 | — | 5.5x#10 | — | — | -164.3%#15 | — | -8.6%#6 | — | — | — | — |
| TNGX | $4.0B#11 | — | 3.9x#4 | 64.6x#7 | 48.3%#5 | 22.0%#7 | -178.4%#6 | -9.9%#8 | — | — | 213.5%#3 | — |
| ABCL | $3.9B#12 | — | 4.4x#6 | 52.2x#6 | 160.6%#2 | 10.1%#8 | -289.0%#7 | -16.3%#11 | -28.0%#4 | — | 180.5%#4 | — |
| AMLX | $3.7B#14 | — | 15.5x#15 | — | -100.0%#10 | 52.0%#5 | — | -60.5%#14 | — | — | 161.0%#7 | — |
| IDYA | $3.7B#13 | — | 3.1x#1 | 17.1x#4 | 3024.4%#1 | 58.6%#4 | -72.8%#5 | -9.5%#7 | — | — | 58.6%#10 | — |
| ELVN | $3.7B#15 | — | 4.1x#5 | — | — | -16.5%#9 | — | -11.6%#9 | — | — | 163.0%#6 | — |
| OGN | $3.6B#16 | 17.5x#2 | 3.6x#2 | 0.6x#1 | -2.9%#7 | -78.4%#13 | 14.9%#3 | 18.6%#2 | 4.9%#2 | 5#1 | 34.2%#12 | 2.4%#1 |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice